What the FDA Has Said About BPC-157 and Compounding In September 2023, the FDA put BPC-157 in Category 2 of the 503A Interim Bulks Guidance, which stopped pharmacies from compounding it
This means the cells responsible for repair become more sensitive to growth hormone already circulating in your body
Professional Guidance: Healthcare professionals can tailor MIC treatment plans based on individual needs, ensuring safety and effectiveness
Licensed alternatives for weight management, including semaglutide (Wegovy) and liraglutide (Saxenda), are available through regulated NHS and private pathways following NICE appraisal
Rare allergic reactions (particularly in individuals sensitive to sulfa, due to methionine)
Theyre not magic bullets but when used correctly, they can be a helpful part of your wellness toolkit